文献速递腹部MR

LI-RADS非放射治疗反应算法2024版:诊断性能与辅助特征的影响

LI-RADS Nonradiation Treatment Response Algorithm Version 2024: Diagnostic Performance and Impact of Ancillary Features.
PubMed 文献 · AJR Am J Roentgenol · 2024-11-13

该回顾性研究纳入231例接受局部治疗的HCC患者共306个病灶,以手术病理为参考,比较LI-RADS非放射治疗反应算法2024版与2017版及mRECIST在MRI上的诊断性能;2024版联合辅助特征诊断病理存活的敏感度和准确率优于不用辅助特征及2017版,特异度优于mRECIST,特异度较不用辅助特征无显著变化。

要点

  • LI-RADS非放射治疗反应算法2024版联合辅助特征诊断病理存活的敏感度85.5%–87.2%、准确率82.7%–83.7%。
  • 联合辅助特征较不用辅助特征提高敏感度和准确率(两名阅片者),特异度无显著变化。
  • 联合辅助特征敏感度高于2017版(两名阅片者),特异度高于mRECIST(两名阅片者)。

核心结论

  • LI-RADS非放射治疗反应算法2024版在检测病理存活方面显示良好的诊断性能。
  • 辅助特征可提高敏感度和准确率,特异度无显著变化。
  • 作者建议使用LI-RADS非放射治疗反应算法2024版联合辅助特征指导局部治疗后的预后评估和治疗决策。

研究设计与样本

  • 回顾性研究,纳入2017年1月至2022年12月接受局部治疗后续行肝切除或肝移植的231例HCC患者(198例男性、33例女性,中位年龄56岁)。
  • 共评估306个治疗病灶,以治愈性手术病理为参考标准,病理存活249个、完全病理坏死57个。
  • 两名放射科医师独立使用LI-RADS非放射治疗反应算法2024版、LI-RADS治疗反应算法2017版和mRECIST评估,LR-TR Equivocal判为测试阴性。
  • 采用Bonferroni校正McNemar检验比较诊断性能。

诊断标准与关键数值

  • LI-RADS非放射治疗反应算法2024版联合辅助特征:阅片者1敏感度85.5%、特异度75.4%、准确率83.7%;阅片者2敏感度87.2%、特异度63.2%、准确率82.7%。
  • LI-RADS非放射治疗反应算法2024版不用辅助特征:阅片者1敏感度81.1%、特异度78.9%、准确率80.7%;阅片者2敏感度80.3%、特异度78.9%、准确率80.1%。
  • LI-RADS治疗反应算法2017版:阅片者1敏感度79.9%、特异度82.5%、准确率80.4%;阅片者2敏感度79.1%、特异度79.0%、准确率79.1%。
  • mRECIST:阅片者1敏感度83.9%、特异度54.4%、准确率78.4%;阅片者2敏感度87.2%、特异度40.4%、准确率78.4%。
  • 联合辅助特征较不用辅助特征敏感度和准确率更高(两名阅片者),敏感度高于2017版(两名阅片者),特异度高于mRECIST(两名阅片者),准确率高于2017版(阅片者2),均p < .008;其余比较无显著差异(p > .008)。

临床应用与阅片要点

  • 作者建议使用LI-RADS非放射治疗反应算法2024版联合辅助特征指导局部治疗后的预后评估和治疗决策。
  • 将LR-TR Equivocal判为测试阴性时,联合辅助特征可提高检出病理存活的敏感度和准确率,特异度无显著变化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. LI-RADS Treatment Response Algorithm (TRA) version 2024 (v2024) introduced separate algorithms for detecting hepatocellular carcinoma (HCC) viability after radiation and nonradiation locoregional therapies (LRTs). The nonradiation algorithm incorporated MRI-based ancillary features to optionally upgrade lesions from LR-TR Equivocal to LR-TR Viable. OBJECTIVE. The purpose of this study was to compare the diagnostic performance of LI-RADS Nonradiation TRA v2024 with that of LI-RADS TRA version 2017 (v2017) and modified RECIST (mRECIST) for evaluating HCC response to LRT on MRI, with attention given to the impact of ancillary features. METHODS. This retrospective study included 231 patients (198 men and 33 women; median age, 56 years) who underwent LRT for HCC followed by liver resection or transplant between January 2017 and December 2022. Two radiologists (reader 1 and reader 2) independently evaluated treated lesions (n = 306) using LI-RADS Nonradiation TRA v2024, LI-RADS TRA v2017, and mRECIST. Lesions were classified as showing pathologic viability (n = 249) or complete pathologic necrosis (n = 57) based on curative surgery pathology. The diagnostic performance for pathologic viability was compared using Bonferroni-adjusted McNemar tests, with LR-TR Equivocal assessments classified as test negative. RESULTS. The sensitivity, specificity, and accuracy for LI-RADS Nonradiation TRA v2024 with ancillary features were 85.5%, 75.4%, and 83.7%, respectively, for reader 1 and 87.2%, 63.2%, and 82.7%, respectively, for reader 2; for LI-RADS Nonradiation TRA v2024 without ancillary features, they were 81.1%, 78.9%, and 80.7%, respectively, for reader 1 and 80.3%, 78.9%, and 80.1%, respectively, for reader 2; for LI-RADS TRA v2017, they were 79.9%, 82.5%, and 80.4%, respectively, for reader 1 and 79.1%, 79.0%, and 79.1%, respectively, for reader 2; and for mRECIST, they were 83.9%, 54.4%, and 78.4%, respectively, for reader 1 and 87.2%, 40.4%, and 78.4%, respectively, for reader 2. LI-RADS Nonradiation TRA v2024 with ancillary features showed higher sensitivity and accuracy than LI-RADS Nonradiation v2024 without ancillary features (both readers), higher sensitivity than LI-RADS TRA v2017 (both readers), higher specificity than mRECIST (both readers), and higher accuracy than LI-RADS TRA v2017 (reader 2) (p < .008); remaining comparisons between LI-RADS Nonradiation TRA v2024 with ancillary features and other systems were not significant (p > .008). CONCLUSION. LI-RADS Nonradiation TRA v2024 showed good diagnostic performance in detecting pathologic viability. Ancillary features yielded improved sensitivity and accuracy without a significant change in specificity. CLINICAL IMPACT. Use of LI-RADS Nonradiation TRA v2024 with ancillary features is recommended for guiding prognostic assessments and treatment decisions after LRT.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Zhou S, Zhou G, Shen Y, et al. LI-RADS Nonradiation Treatment Response Algorithm Version 2024: Diagnostic Performance and Impact of Ancillary Features. AJR Am J Roentgenol. 2024. PMID: 39535775. doi:10.2214/AJR.24.32035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。